Regenerative Medicine and Stem Cells Technologies

This week, a UCSF Benioff Children’s Hospital Oakland’s adult patients underwent a landmark gene editing therapy – marking the first time that genome editing has been done inside a human body in an effort to change the DNA of a patient with a rare genetic disease.

A new way of genetically altering a patient’s cells to fight cancer has helped desperately ill people with leukemia when every other treatment had failed, researchers reported on Monday in the journal Nature Medicine.

Harvard Medical School researchers at Boston Children’s Hospital have reversed type 1 diabetes in mice by infusing blood stem cells pretreated to produce more of a protein called PD-L1, which is deficient in mice and people with type 1 diabetes.

Every chemotherapy agent approved in use in cancer patients has proven its utility against cancer, to varying degrees, but most have significant side effects that can be found in the package insert.

Scientists have tried editing a gene inside the body for the first time, in a bold attempt to tackle an incurable a disease by permanently changing a patient’s DNA.

Stem cells in the body have a significantly different gene-expression profile than do the same cells when they’re isolated in a lab dish, according to researchers at the Stanford University School of Medicine.

Being born into a business family is a matter of coincidence, but taking the legacy to another level after spotting business opportunities in the diverse domains is sheer brilliance.

According to the public relations and information center of the Vice-Presidency for science and technology affairs, Amir Ali Hamidieh, secretary of council for Stem cell sciences and technologies, stated: the third Olympiad on stem cells and regenerative medicine is annually held since 2015 with the financial and spiritual support of council for Stem cell sciences and technologies and the national center for exceptional talents and young researchers as the Organizers of the event.

Strimvelis, a treatment for an ultra-rare inherited immune deficiency condition that has been dubbed ‘bubble baby syndrome’ has been approved by NICE in draft guidance

Results from two early clinical trials show that it may be possible to use human embryonic stem cells as treatment for the dry form of macular degeneration, according to presentations given today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology